Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.


Soft Tissue Sarcoma (STC)

Soft tissue sarcoma (STS) represents a rare and intricate collection of cancerous tumors arising from soft tissues, encompassing muscles, adipose tissue, nerves, and blood vessels. Our company takes a comprehensive approach, leveraging cutting-edge technologies and profound expertise to facilitate the identification of therapeutic targets, the advancement of innovative therapies, and the generation of pertinent animal models for preclinical research.

Overview of Soft Tissue Sarcoma (STC)

Soft tissue sarcoma (STS) encompasses a wide range of malignant tumors that originate from mesenchymal cells. These tumors can manifest in different areas of the body, such as the extremities, trunk, head, and neck. While STS can affect individuals of all age groups, it is typically more commonly diagnosed in adults. The annual incidence of STS varies between 1.8 to 5.0 cases per 100,000 population.

Distribution of histiotypes of soft tissue sarcoma in adults.Fig. 1 Distribution of histiotypes of soft tissue sarcoma in adults. (Gamboa A. C., et al., 2020)

Types of Soft Tissue Sarcoma (STC)

Alveolar soft part sarcoma Atypical lipomatous tumor
Angiosarcoma of soft tissue Clear cell sarcoma of soft tissue
Dermatofibrosarcoma protuberans Dermatofibrosarcoma protuberans, fibrosarcomatous
Desmoplastic small round cell tumor
Epithelioid sarcoma Extraskeletal Ewing sarcoma
Extrarenal rhabdoid tumor Extraskeletal myxoid chondrosarcoma
Extraskeletal osteosarcoma Fibrosarcoma (includes adult and sclerosing epithelioid varieties)
Gastrointestinal stromal tumor, malignant (GIST) Giant cell tumor of soft tissues
Giant cell fibroblastoma
Hemangioendothelioma Interdigitating dendritic cell sarcoma
Inflammatory myofibroblastic tumor Leiomyosarcoma
Intimal sarcoma Liposarcoma
Low-grade fibromyxoid sarcoma Low-grade myofibroblastic sarcoma
Malignant ossifying fibromyxoid tumor Malignant phosphaturic mesenchymal tumor
Malignant peripheral nerve sheath tumor Malignant Triton tumor
Malignant glomus tumor Malignant solitary fibrous tumor
Malignant granular cell tumor Myoepithelial carcinoma
Myxofibrosarcoma (formerly myxoid malignant fibrous histiocytoma) Perivascular epithelioid cell tumor, not otherwise specified
Rhabdomyosarcoma Synovial sarcoma
Stromal sarcoma not otherwise specified Undifferentiated epithelioid sarcoma
Undifferentiated round cell sarcoma Undifferentiated sarcoma, not otherwise specified
Undifferentiated pleomorphic sarcoma Undifferentiated spindle cell sarcoma

Targets of Soft Tissue Sarcoma (STC) Therapy

Ras Pathway

Activation of the Ras pathway has been implicated in the development of undifferentiated pleomorphic sarcoma (UPS). Targeting this pathway may offer potential therapeutic benefits for UPS.

PI3K-AKT Pathway

Genetic alterations in the PI3K-AKT signaling pathway, such as PTEN inactivation, have been observed in leiomyosarcomas. Inhibiting this pathway holds promise as a targeted therapy for leiomyosarcoma.

mTOR Pathway

The mTOR pathway plays a crucial role in cell growth and proliferation. Inhibitors targeting this pathway have shown promising results in preclinical models and clinical trials for the treatment of leiomyosarcoma and other soft tissue sarcomas.


Soft tissue sarcomas often exhibit increased angiogenesis, which is crucial for tumor growth and metastasis. Targeting angiogenic factors, such as VEGF, has shown potential in inhibiting tumor angiogenesis and suppressing soft tissue sarcoma progression.

Therapies of Soft Tissue Sarcoma (STC)

  • Targeted Therapies
    Tyrosine kinase inhibitors have proven to be a valuable therapeutic strategy in the treatment of specific subtypes of soft tissue sarcoma. One notable example is pazopanib, which acts as a TKI targeting various kinases involved in angiogenesis and cell proliferation, including vascular endothelial growth factor receptors (VEGFR), and platelet-derived growth factor receptors (PDGFR), among others.
  • Immunotherapies
    Immunotherapies harness the body's immune system to recognize and eliminate cancer cells. In soft tissue sarcoma, immune checkpoint inhibitors have shown promise in a subset of patients. These inhibitors, such as pembrolizumab and nivolumab, block proteins like PD-1 or PD-L1, thereby reactivating the immune response against tumor cells.

Our Services

As a leading company in the field of rare disease drug and therapy development, Our company is dedicated to providing advanced diagnostics and therapy development services for soft tissue sarcoma (STS).

Therapy Development Platforms

Animal Models of Soft Tissue Sarcoma (STS)

Our company has a dedicated team of scientists experienced in the development of relevant animal models for preclinical research. These models accurately recapitulate the biology and behavior of soft tissue sarcomas, enabling the evaluation of potential therapies in a controlled and predictive environment.

Xenograft Model Development
Xenograft models involve the transplantation of human soft tissue sarcoma cells or tissues into immunodeficient mice. Our company provides xenograft models for various subtypes of soft tissue sarcoma, including leiomyosarcoma, liposarcoma, and synovial sarcoma, among others.
Genetic Engineering Model Development
Genetically engineered mouse models (GEMMs) play a crucial role in understanding the underlying mechanisms and genetic alterations driving soft tissue sarcoma development. Our company offers GEMMs that mimic specific genetic alterations observed in human STS.
Optional Species Mouse, Rat, Others

In addition, we also provide other customized animal models to meet diverse needs. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Gamboa, Adriana C., Alessandro Gronchi, and Kenneth Cardona. "Soft‐tissue sarcoma in adults: an update on the current state of histiotype‐specific management in an era of personalized medicine." CA: a cancer journal for clinicians 70.3 (2020): 200-229.
  • Nakano, Kenji, and Shunji Takahashi. "Precision medicine in soft tissue sarcoma treatment." Cancers 12.1 (2020): 221.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions

Copyright © Protheragen. All rights reserves.